Dr. Laurent Claret Will Present Case Studies on the Value of Drug-Disease Modeling to Predict Efficacy and Survival Benefits of Anticancer Agents
MOUNTAIN VIEW, Calif., June 12 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Laurent Claret, Ph.D., senior scientist, Pharsight Strategic Consulting Services, will speak to members of the pharmaceutical and biotechnology industries attending the Population Approach Group in Europe (PAGE) 17th Annual Meeting. The PAGE meeting will be held at the Medical School of Marseille in Marseilles, France from June 18-20, 2008.
Dr. Claret will present two oncology case studies during a dedicated
conference session on applications in model-based development:
-- June 18: A Modeling Framework to Simulate Xeloda Dose Intensity and
Survival in Colorectal Cancer. Dr. Claret will present this case study
as part of an oral conference session on the strategic use of modeling
and simulation in oncology. The session will include applied examples
of drug-disease modeling and will describe research on how
quantitative, model-based approaches have been used to support dosing
decisions of anticancer therapies in clinical practice. Rene Bruno,
Ph.D., managing director, Pharsight Strategic Consulting Services,
Europe, serves as conference chair for the oncology session.
-- June 19: Modeling and Simulation to Assess the Use of Change in Tumor
Size as Primary Endpoint in Phase II Studies in Oncology. Dr. Claret
will present this case stu
|SOURCE Pharsight Corporation|
Copyright©2008 PR Newswire.
All rights reserved